Wire · opportunities
SK bioscience Seeks South Africa Approval to Begin Phase 1b Trial of RSV Preventive ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
SK bioscience has submitted a clinical trial application to South Africa to begin a Phase 1b global pediatric trial of RSM01, an RSV preventive antibody candidate licensed from the Gates Medical Research Institute. The trial will evaluate safety and pharmacokinetics in infants aged 2 weeks to 8 months, marking the company’s expansion from vaccines into antibody-based infectious disease prevention.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 14 Aug 2026 and 17 Aug 2026.
◆ ◆ The Wire takeaway
You need to prepare for emerging demand in antibody-based RSV prevention as SK bioscience expands clinical trials into Africa. This opens new regulatory pathways and market opportunities beyond vaccines in pediatric infectious disease.
◆ Coverage
2 sources · first reported 14 Aug 2026 · latest 17 Aug 2026
◆ Related on Wire
◆ Topics